bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2024.06.06.597698

Optimal control of Multiple Myeloma assuming drug evasion and off-target effects

Lefevre, J.·Lawson, B. A. J.·Burrage, P. M.·Donovan, D. M.·Burrage, K.
View original source ↗Export metadata ↓

Abstract

Multiple Myeloma (MM) is a plasma cell cancer that occurs in the bone marrow. A leading treatment for MM is the monoclonal antibody Daratumumab, targeting the CD38 receptor, which is highly overexpressed in myeloma cells. In this work we model drug evasion via loss of CD38 expression, which is a proposed mechanism of resistance to Daratumumab treatment. We develop an ODE model that includes drug evasion via two mechanisms: a direct effect in which CD38 expression is lost without cell death in response to Daratumumab, and an indirect effect in which CD38 expression switches on and off in the cancer cells; myeloma cells that do not express CD38 have lower fitness but are shielded from the drug action. The model also incorporates competition with healthy cells, death of healthy cells due to off-target drug effects, and a Michaelis-Menten type immune response. Using optimal control theory, we study the effect of the drug evasion mechanisms and the off-target drug effect on the optimal treatment regime. We identify a general increase in treatment duration and costs, with varying patterns of response for the different controlling parameters. Several distinct optimal treatment regimes are identified within the parameter space. Author summaryIn this work we investigate a model of Multiple Myeloma, a cancer of the bone marrow, and its treatment with the drug Daratumumab. The model incorporates proposed mechanisms by which the cancer evades Daratumumab by reduced expression of the receptor CD38, which is the drug target and normally abundent in the cancer cells. The model includes an off-target effect, meaning that the drug treatment destroys some healthy cells alongside the targeted cancer cells. Both mechanisms can reasonably be expected to reduce the efficacy of the drug. We investigate the model using optimal control methods, which are used to find the drug dose over time which best balances the financial and health costs of treatment against cancer persistence, according to a specified cost function. We show that this drug resistence and off-target effect prolongs the optimal treatment and increase the burden of both the disease and drug. We analyse the distinct effects of the controlling parameters on each of these costs factors as well as the time course, and identify conditions under which extended treatment is required, with either intermittant treatment or a steady reduced dose. Extended treatment may be indefinite or for a fixed period.

Explore related subjects

systems biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lefevre, J., Lawson, B. A. J., Burrage, P. M., Donovan, D. M., Burrage, K.. 2024-06-09. Optimal control of Multiple Myeloma assuming drug evasion and off-target effects. https://doi.org/10.1101/2024.06.06.597698

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Parsimonious Creatures: Building Gene Regulatory Networks Robust to Somatic Evolution

For early multicellular life to have formed and maintained cellular organization, preventing loss of controlled cell replication due to somatic evolution was of critical importance, and remains important to this day for control of cancer. We study how gene regulatory networks (GRNs) can be designed to slow the divergence of somatic clonal lineages in the context of early multicellular life. We model the mutation of GRNs within simplified 12-celled organisms we term "parsimonious creatures", who must replicate from a single cell to 12 cells and then prevent replication past 12 cells to maximize fitness. We found two minimal motifs can achieve these goals, but both are prone to breakdown through somatic evolution: The feedforward motif, which is loosely regulating but relatively robust, and the simple step motif, which uses strong interactions and feedback to form memoryless ultrasensitivity, but is fragile. These simple motifs may be duplicated to form redundant networks via one of two structures: averaging redundancy, which averages multiple sources of information, and min redundancy, which adopts the most conservative source. Averaging redundancy uniformly slows somatic evolution, while min redundancy stalls somatic evolution until neutral mutations accumulate. Either may be superior dependent on life history. However, averaging redundancy slowly increases fitness as the network becomes larger, but large min redundancy networks eventually become "paralyzed", increasing the probability of senescence and reducing fitness. These GRN designs are idealized, yet provide imperfect solutions with fundamental tradeoffs, offering insight as to why somatic evolution remains an incompletely solved problem for multicellular life.

systems biology↗
bioRxiv2026

Homogeneous network inference for subtype-stratified master regulator analysis in cancer

Master-regulator analysis of 34 TCGA tumour cohorts (cancer x molecular subtype; n between 27 and 562 tumours) requires one regulatory network per cohort. Mutual-information (MI) networks inferred with ARACNe3 are the usual choice, but they are not available for the smallest cohorts; filling the gap with correlation networks would mix two methods inside the very comparison between subtypes that the analysis is meant to make. We therefore infer every network with a single procedure, fixed-size Spearman regulons (FSR): rank correlation between regulator and target, a fixed effect-size threshold rho >= 0.2, the per-target data-processing-inequality (DPI) pruning implemented in corto, bootstrap support, and truncation to the 100 best-supported targets per regulator. We quantify what this choice concedes and what it provides, labelling each claim as a standard result, a heuristic, or an empirical result. Rank correlation is more powerful than the MI estimators we simulated for n < 200 but cannot see non-monotone dependence, which in a synthetic worst case costs at most about 0.05-0.10 of the master regulators recovered; the per-target DPI is a heuristic with a measurable disagreement rate with the MI-based one; and pairwise dependence is not direct interaction, for MI and correlation alike. Where both methods are feasible (n >= 95) they overlap in 0.7 of the top-20 regulators, the same as two filterings of the same ARACNe3 network, although the rank correlation of the full score vector shows a measurable method effect in the tail. Subsampling large real cohorts indicates that networks inferred from fewer than 60 tumours do not reliably reproduce their own cohort's master regulators, that 60-100 is a grey zone, and that a cancer-wide network does not rescue small subtypes. We present FSR as an adequate and uniform choice for multi-cohort analysis, not as a statistically superior one.

systems biology↗
bioRxiv2026

Low-fidelity simulator selection for multi-fidelity inference of epithelial vertex models

Vertex models link cell division, neighbour exchange, and intercellular forces to epithelial tissue form through parameters such as junctional line tension and perimeter contractility. Bayesian inference of these parameters from data quantifies their uncertainty, but for stochastic models of proliferating tissues it requires many costly simulations. Multi-fidelity simulation-based inference reduces this cost by training on many runs of a cheaper, less accurate ('low-fidelity') simulator before refining with a few full ('high-fidelity') runs. Low-fidelity versions can be constructed in several ways, for example by stopping simulations early, coarsening the timestep, or averaging fewer replicates, but it is unclear which to choose before committing to costly training. To address this, we introduce PRISM (Paired Ranking Index for Simulator Matching), a screen that compares each candidate with the full simulator on paired runs, scoring agreement in cell-packing statistics against cost. For a vertex model of a proliferating tissue, PRISM flags stopping early as unreliable before training; once trained, this choice can produce confidently wrong parameter estimates. By contrast, a coarser timestep, within the range tested, is cheap and accurate; while fewer replicates are accurate but too costly. Using a screened low-fidelity simulator, multi-fidelity inference outperforms approximate Bayesian computation and neural-network inference trained on full simulations alone, at matched cost and with well-calibrated uncertainty. The same pattern recurs for a second vertex model fitted to published Drosophila pupal-wing imaging data, although there stopping halfway proves safe. Together, our findings suggest that which approximations are safe depends on the model, and that screening them before training makes multi-fidelity inference of tissue mechanics practical.

systems biology↗